Related Experiment Videos
Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices
N Jeandidier1, S Boivin, R Sapin
1Service d'Endocrinologie et des Maladies de la Nutrition, Hôpitaux Universitaires, Hôpital Civil, Strasbourg, France.
Diabetologia
|May 1, 1995
Summary
Intraperitoneal insulin infusion in insulin-dependent diabetic patients significantly increases anti-insulin antibodies. While severe hypoglycemia decreased, responders showed poorer metabolic control compared to non-responders.
Area of Science:
- Immunology
- Endocrinology
- Medical Devices
Background:
- Intraperitoneal insulin infusion shows promise for diabetic control and reducing hypoglycemia.
- Preliminary data indicate a significant rise in anti-insulin antibodies with this therapy.
Purpose of the Study:
- To evaluate the immunogenicity of intraperitoneal insulin infusion.
- To assess the consequences of anti-insulin antibody formation on metabolic control in IDDM patients.
Main Methods:
- Assessed anti-insulin antibody levels in 62 IDDM patients over 2 years post-pump implantation.
- Monitored diabetes control via HbA1c, mean blood glucose, glucose variability, and hypoglycemia frequency.
- Investigated factors influencing antibody formation: age, gender, HLA typing, and complement C4 alleles.
Main Results:
- Anti-insulin antibody levels rose significantly post-implantation, from 3.14% to 8.34% after 1 year.
- Non-responders (antibody titre <6%) exhibited significantly better metabolic control than responders (antibody titre >15%).
- Severe hypoglycemia decreased in both groups; insulin requirements remained low for non-responders but returned to baseline for responders.
Conclusions:
- Intraperitoneal insulin infusion elicits a strong immunogenetic response in approximately half of IDDM patients.
- This immune response has moderately deleterious effects on metabolic control, particularly in responders.
- Despite antibody formation, the therapy effectively reduced severe hypoglycemia.